Dutch medtech company Salvia BioElectronics secured $60 million in Series B funding to accelerate clinical development and launch of MySalvia Therapy—a neuromodulation treatment using an ultra-thin implant targeting key nerves involved in migraines.
MySalvia features a wearable external device that activates personalized nerve stimulation on demand, offering patients control over reducing migraine frequency and intensity. The company is also developing an app for treatment monitoring and customization.
Led by Innovation Industries, the round includes Invest-NL, EIC Fund, and existing investors. The therapy is currently under evaluation in the RECLAIM study and has FDA breakthrough device designation.
MySalvia’s minimally invasive implant is placed beneath the skin on the forehead and back of the head, promising reduced surgical complexity, faster recovery, and discreet use. Salvia aims for regulatory approvals in the U.S., Europe, and Australia.
Founder Hubert Martens emphasized the mission to restore freedom for chronic migraine sufferers with meaningful, lasting relief.
Follow MEDWIRE.AI for updates on innovative neurological therapies.
